Supplementary Information for:

Herd immunity induced by COVID-19 vaccination programs to suppress epidemics caused by SARS-CoV-2 wild type and variants in China

Hengcong Liu[1]*, Juanjuan Zhang [1,2]*, Jun Cai[1], Xiaowei Deng[1], Cheng Peng[1], Xinghui Chen[1], Juan Yang[1,2,3], Qianhui Wu[1], Zhiyuan Chen[1], Wen Zheng[1], Cécile Viboud[4], Wenhong Zhang[1†], Marco Ajelli[5,6†] and Hongjie Yu[1,2,3†]

1. Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China
2. Key Laboratory of Public Health Safety, Fudan University, Ministry of Education, Shanghai, China
3. Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China
4. Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD, USA
5. Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA
6. Laboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University, Boston, MA, USA

*These authors contributed equally to this work.

[†]These authors are joint senior authors contributed equally to this work.

Corresponding authors: Hongjie Yu, Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health, Fudan University, Shanghai 200032, China

E-mail: yhj@fudan.edu.cn

Contents

1 SARS-CoV-2 transmission and vaccination model 4

2 Transmission rate and basic reproduction number in the absence of NPIs 13

3 Estimation of the effective reproduction number ($\boldsymbol{Re}$) 14

4 Vaccine contraindication and pregnant women 15

5 Vaccine administration capacity 18

6 Additional results for the baseline analysis 20

7 Sensitivity analyses 22

7.1 leaky vaccine 22

7.2 Initial number of infected individuals 23

7.3 Homogeneous susceptibility to infection by age 24

7.4 Natural immunity 25

7.5 Vaccine efficacy 26

7.6 Time interval between the two doses 28

8 Scenario 1: Delaying the start of the epidemic 29

9 Scenario 2: Adopting NPIs in case of a new outbreak 31

10 Scenario 3: Delaying the start of the epidemic and adopting NPIs 32

11 Additional results about the herd immunity threshold 33

12 US-like scenario 35

13 SI References 36

1 SARS-CoV-2 transmission and vaccination model

Transmission and vaccination model

We developed an age-stratified stochastic susceptible-infectious-removed model of SARS-CoV-2 transmission. The population is divided into 17 age groups with 16 5-year age groups from 0 to 79 years and 1 age group for individuals aged 80 years or older. Age-mixing patterns were derived from a contact survey study conducted in Shanghai in 2017-2018 [1]. The model is used to simulate a set of vaccination programs.



Figure S1. Schematic figure of SARS-CoV-2 transmission and vaccination model. Compartments used in the model include (take age group $a \in [1, 17]$ at time t as an example): unvaccinated susceptible individuals $S_a(t)$, unvaccinated infected individuals $I_a(t)$, unvaccinated removed individuals $R_a(t)$, individuals who have received one vaccine dose $V_a^1(t)$, unprotected vaccinated individuals who have received two doses $V_{a,s}^2(t)$, temporarily unprotected vaccinated individuals who have received two doses and will gain protection 14 days later $V_{a,p}^2(t)$, protected vaccinated individuals who have received two doses $V_{a,r}^2(t)$, vaccinated infected individuals $I_a^V(t)$, and vaccinated removed individuals $R_a^V(t)$. Note that

vaccinated individuals are defined as those administered 2 doses. Parameters used in the model include: time- and age-dependent force of infection $\lambda_a(t)$, recovery rate from infection γ, relative vaccine efficacy against infection right after administration of 2nd dose p_v as compared with maximum protection (i.e., after the ramp-up of the 2nd dose) ϵ_v, and vaccine efficacy of age group a relative to adults aged 18-59 years ($r_{\epsilon_{v,a}}$), probability of administration of 1st dose (α_a), time interval between administration of first and second dose ($1/\omega_0$) and maximum protection ($1/\omega_1$).

The SARS-CoV-2 transmission and vaccination model is schematically represented in Figure S1 and it is described by the following differential equations:

$$\dot{S_a} = -\lambda_a S_a - \alpha_a S_a \tag{1}$$

$$\dot{I_a} = \lambda_a S_a + \lambda_a V_a^1 - \gamma I_a \tag{2}$$

$$\dot{R_a} = \gamma I_a \tag{3}$$

$$\dot{\mathrm{V}_a^1} = \alpha_a S_a - \lambda_a \mathrm{V}_a^1 - \omega_0 \mathrm{V}_a^1 \tag{4}$$

$$\dot{\mathrm{V}_{a,s}^2} = \left(1 - r_{\epsilon_{v,a}} \epsilon_v\right) \omega_0 \mathrm{V}_a^1 - \lambda_a \mathrm{V}_{a,s}^2 \tag{5}$$

$$\dot{\mathrm{V}_{a,p}^2} = (1 - p_v) r_{\epsilon_{v,a}} \epsilon_v \omega_0 \mathrm{V}_a^1 - \lambda_a \mathrm{V}_{a,p}^2 - \omega_1 \mathrm{V}_{a,p}^2 \tag{6}$$

$$\dot{\mathrm{V}_{a,r}^2} = p_v r_{\epsilon_{v,a}} \epsilon_v \omega_0 \mathrm{V}_a^1 + \omega_1 \mathrm{V}_{a,p}^2 \tag{7}$$

$$\dot{I_a^V} = \lambda_a \mathrm{V}_{a,s}^2 + \lambda_a \mathrm{V}_{a,p}^2 - \gamma I_a^V \tag{8}$$

$$\dot{R_a^V} = \gamma I_a^V \tag{9}$$

where:

- S_a represents the unvaccinated susceptible individuals.
- I_a represents the unvaccinated infected individuals.
- R_a represents the unvaccinated removed individuals.
- V_a^1 represents the individuals who have received one vaccine dose.

- $V_{a,s}^{2}$ represents the unprotected vaccinated individuals who have received two doses.
- $V_{a,p}^{2}$ represents the temporarily unprotected vaccinated individuals who have received two doses and will gain protection 14 days later.
- $V_{a,r}^{2}$ represents the protected vaccinated individuals who have received two doses.
- I_a^V represents the vaccinated infected individuals.
- R_a^V represents the vaccinated removed individuals.
- λ_a represents the time- and age-dependent force of infection.
- γ represents the recovery rate, which corresponds to the length of the generation time in an SIR model [2]; we consider an average generation time of 7 days [3].
- ϵ_v represents the maximum protection (i.e., after the ramp-up of the 2nd dose).
- p_v represents relative vaccine efficacy against infection right after administration of 2nd dose as compared with maximum protection.
- $r_{\epsilon_{v,a}}$ represents vaccine efficacy of age group a relative to adults aged 18-59 years.
- α_a represents the probability of administration of 1st dose.
- $1/\omega_0$ represents time interval between administration of first and second dose.
- $1/\omega_1$ represents maximum protection.

The time- and age-dependent force of infection $\lambda_a(t)$ to which susceptible individuals of age group a are exposed to SARS-CoV-2 infection is defined as:

$$\lambda_a(t) = \beta \varepsilon_a \sum_{\tilde{a}} C_{a,\tilde{a}} \frac{I_{\tilde{a}} + I_{\tilde{a}}^V}{N_{\tilde{a}}} \tag{10}$$

Where:

- β is a scaling factor shaping SARS-CoV-2 transmissibility.

- ε_a is the relative susceptibility to SARS-CoV-2 infection of age group a.
- $C_{a,\tilde{a}}$ represents the age-group-specific contact matrix, whose elements describe the daily mean numbers of that a person in age group a has with individuals in age group $\tilde{a}$.
- N_a represents the number of individuals of age group a.

Considering the daily vaccination capacity (see Sec. 5 of *SI Appendix*), we prioritize those individuals who need to receive the 2nd dose at time t, then the remaining daily capacity is randomly allocated to those who are eligible to receive the 1st dose. At each time t, the first dose of vaccinations is administrated to a fraction of susceptible individuals in the population in age group *a*:

$$\alpha_a = \frac{d_a(t)}{S_a(t)} \tag{11}$$

where $d_a(t)$ represents the number of first doses to be allocated to individuals in age group *a* at time t under the designed vaccination strategies.

Disease burden

To quantify COVID-19 burden, we estimated the age dependent ratio between:

- symptomatic and infected individuals among unvaccinated and vaccinated individuals, respectively (π, π_v).
- hospitalized cases and infected individuals among non-vaccinated and vaccinated individuals, respectively (Σ, Σ_v).
- ICU cases and infected individuals among non-vaccinated and vaccinated individuals, respectively (Θ, Θ_v).

- death cases and infected individuals among non-vaccinated and vaccinated individuals, respectively (M, M_v).

We then used the following equations:

$$\Sigma = \pi * \sigma \tag{12}$$

$$\Theta = \pi * \sigma * \theta \tag{13}$$

$$M = \pi * \mu \tag{14}$$

Where

- σ represents the ratio between hospitalized cases and laboratory-confirmed symptomatic infections.
- θ represents the ratio between cases requiring ICU and hospitalized cases.
- μ represents the fatality ratio among laboratory-confirmed symptomatic infections.

When considering vaccine efficacy against each disease metric, the equations becomes:

$$\pi_v = \pi * (1 - \epsilon_{v,\pi}) \tag{15}$$

$$\Sigma_v = \Sigma * (1 - \epsilon_{v,\Sigma}) \tag{16}$$

$$\Theta_v = \Theta * (1 - \epsilon_{v,\Theta}) \tag{17}$$

$$M_v = M * (1 - \epsilon_{v,M}) \tag{18}$$

Where

- $\epsilon_{v,\pi}$ represents the vaccine efficacy in preventing symptomatic disease given infection.
- $\epsilon_{v,\Sigma}$ represents the vaccine efficacy in preventing hospitalization given infection.
- $\epsilon_{v,\Theta}$ represents the vaccine efficacy in preventing ICU admission given infection.
- $\epsilon_{v,M}$ represents the vaccine efficacy in preventing death given infection.

When considering vaccine efficacy in preventing each disease metric, we then used the following equations to estimate the different vaccine efficacies:

$$\epsilon_v^s = \epsilon_v + (1 - \epsilon_v)\epsilon_{v,\pi} \tag{19}$$

$$\epsilon_v^h = \epsilon_v + (1 - \epsilon_v)\epsilon_{v,\Sigma} \tag{20}$$

$$\epsilon_v^i = \epsilon_v + (1 - \epsilon_v)\epsilon_{v,\Theta} \tag{21}$$

$$\epsilon_v^d = \epsilon_v + (1 - \epsilon_v)\epsilon_{v,M} \tag{22}$$

Where

- ϵ_v represents the vaccine efficacy in preventing the infection.
- ϵ_v^s represents the vaccine efficacy in preventing symptomatic disease.
- ϵ_v^h represents the vaccine efficacy in preventing hospitalization.
- ϵ_v^i represents the vaccine efficacy in preventing ICU admission.
- ϵ_v^d represents the vaccine efficacy in preventing death.

A summary of model parameters is reported in Table S1 and S2.

Table S1. Summary of parameters used to model historical SARS-CoV-2 lineages.

Description	**Baseline analysis**	**Sensitivity analysis**
Epidemiology		
Average generation time ($\mathbf{1/\gamma}$)	7 days (95% CI: 3.6-11.3) [3]	-
Basic reproduction number ($\boldsymbol{R_0}$)	2.5 [4-7]	-
reproduction number in a fully susceptible population and under certain NPIs ($\boldsymbol{R_0^{NPIs}}$)	1.1, 1.3, 1.5, 1.7, 1.9, 2.1, 2.3	-

Initially infected individuals	40 [8]	10, 20, 100
Initial natural immunity	0 [9]	10%, 20%, 30%
Relative susceptibility to infection by age ($\boldsymbol{\varepsilon_a}$)	0.58 (95% CI 0.34-0.98) for $a < 15$; 1 for $15 \leq a < 65$; 1.65 (95% CI 1.03-2.65) for $a \geq 65$ [10].	Homogeneous susceptibility
Epidemic start date	Sep 1, 2021	Oct 1, 2021, Nov 1, 2021
Vaccination		
Interval between the administration of 1st and 2nd dose ($\boldsymbol{1/\omega_0}$)	21 days [11]	14 days
Delay between the administration of the 2nd dose of vaccination and maximum protection ($\boldsymbol{1/\omega_1}$)	14 days [11]	-
Vaccine efficacy in preventing the infection for individuals aged 18-59 years ($\boldsymbol{\epsilon_v}$)	73.5% [11]	0.6, 0.84
Relative vaccine efficacy against infection right after administration of 2nd dose as compared with maximum protection ($\boldsymbol{p_v}$)	83.8% [a 12]	-
Relative vaccine efficacy for individuals aged < 18 and > 59 years as compared to individuals aged 18-59 years ($\boldsymbol{r_{\epsilon_v,a}}$)	100%	75%, 50%
Vaccine efficacy in preventing symptomatic cases for individuals aged 18-59 years ($\boldsymbol{\epsilon_v^s}$)	78.1% [11]	-

Vaccine efficacy in preventing hospitalization for individuals aged 18-59 years ($\boldsymbol{\epsilon_v^h}$)	100% [11]	-
Vaccine efficacy in preventing the need for an ICU admission for individuals aged 18-59 years ($\boldsymbol{\epsilon_v^i}$)	100% [11]	-
Vaccine efficacy in preventing death for individuals aged 18-59 years ($\boldsymbol{\epsilon_v^d}$)	100% [11]	-
Daily vaccination capacity	See section 5	-
Disease burden		
Ratio between symptomatic and infected individuals among unvaccinated individuals ($\boldsymbol{\pi}$)	18.1%, 22.4%, 30.5%, 35.5%, and 64.6% for 0-19, 20-39, 40-59, 60-79, and 80+ years [13]	-
Ratio between hospitalized cases and infected individuals among unvaccinated individuals ($\boldsymbol{\sigma}$)	40.0%, 29.2%, 33.3%, and 33.8% for 0-19, 20-39, 40-59, and 60+ years [14]	-
Ratio between ICU cases and infected individuals among unvaccinated individuals ($\boldsymbol{\theta}$)	0, 2.2%, 7.2%, and 20.9% for 0-14, 15-49, 50-64, and 65+ years [15]	-
Ratio between death and infected individuals among unvaccinated individuals ($\boldsymbol{\mu}$)	0.51%, 0.65%, 2.38%, and 10.52% for 0-19, 20-39, 40-59, and 60+ years [14]	-

[a] Considering that only efficacy 14 days after the second-dose was reported in the literature (73.5% for BBIBP-Corv [11]), we assume that individuals could be protected with a lower efficacy within 0-13 days after the second dose. In order to estimate the efficacy over time for BBIBP-Corv, we refer to another inactivated vaccine used in China (i.e., CoronaVac with 2 doses and 14 days apart). The efficacy for 0-13 days after second-dose and 14 days after second-dose are 42.5% and 50.7%, respectively [12]. Thus, the efficacy within 0-13 days after second-dose in our main analysis is inferred as 73.5% * (42.5%/50.7%) = 61.6%, while we assume that there is no protection before 14 days since the administration of the second dose.

Table S2. Basic reproduction number of the four variants of concern analyzed in this study.

Description	**Value (or range)**	**Sensitivity analysis**
Epidemiology		
Basic reproduction number for Alpha variant ($\boldsymbol{R_0}$)	4 [a 16-22]	-
Basic reproduction number for Beta variant ($\boldsymbol{R_0}$)	3.8 [b 23]	-
Basic reproduction number for Gamma variant ($\boldsymbol{R_0}$)	5.0 [c 24]	-
Basic reproduction number for Delta variant ($\boldsymbol{R_0}$)	6.0 [d 25-27]	-

[a] Estimated based on pooled conclusion [16-22] that the transmissibility of Alpha is 60% higher as compared with that of historical lineages.

[b] Estimated based on the conclusion [23] that the transmissibility of the Beta variant is 50% higher as compared with that of historical lineages.

[c] Estimated based on the conclusion [24] that the transmissibility of the Gamma variant is 100% higher as compared with that of historical lineages.

[d] Estimated based on the conclusion [25-27] that the transmissibility of the Delta variant is 50% higher as compared with that of the Alpha variant.

2 Transmission rate and basic reproduction number in the absence of NPIs

The basic reproduction number R_0 with age structure can be computed by using the Next-Generation matrix (NGM) approach [28] as:

$$R_0 = \frac{\beta}{\gamma}\rho(K_1) \tag{23}$$

Where $\rho(K_1)$ presents the dominant eigenvalue of combined matrix K_1,

$$K_1 = \begin{bmatrix} \varepsilon_1 C_{11}\frac{N_1}{N_1} & \cdots & \varepsilon_1 C_{1n}\frac{N_1}{N_n} \\ \vdots & \ddots & \vdots \\ \varepsilon_n C_{n1}\frac{N_n}{N_1} & \cdots & \varepsilon_n C_{nn}\frac{N_n}{N_n} \end{bmatrix}_{17} \tag{24}$$

Thus, infectious rate β can be computed based on equation from (23) as

$$\beta = \frac{\gamma \times R_0}{\rho(K_1)} \tag{25}$$

3 Estimation of the effective reproduction number (R_e)

The effective reproduction number R_e accounts for the immunity in the population (either natural or from vaccination). It can be computed by using the Next-Generation matrix (NGM) approach [28] as follows:

$$R_v = \frac{\beta}{\gamma}\rho(K_2) \tag{26}$$

Where $\rho(K_2)$ presents the dominant eigenvalue of combined matrix K_2,

$$K_2 = \begin{bmatrix} \varepsilon_1 C_{11}\frac{N_1 - N_1 * c_1 * \epsilon_v}{N_1} & \cdots & \varepsilon_1 C_{1n}\frac{N_1 - N_1 * c_1 * \epsilon_v}{N_\mathrm{n}} \\ \vdots & \ddots & \vdots \\ \varepsilon_n C_{n1}\frac{N_n - N_n * c_n * \epsilon_v}{N_1} & \cdots & \varepsilon_n C_{nn}\frac{N_n - N_n * c_n * \epsilon_v}{N_\mathrm{n}} \end{bmatrix}_{17} \tag{27}$$

Where c_a represents the vaccine coverage of age group a and ϵ_v represents the vaccine efficacy in preventing the infection.

4 Vaccine contraindication and pregnant women

All individuals with vaccine contraindications and pregnant women are excluded from the target population of the simulated vaccination programs. Vaccine contraindications are defined according to the guideline reported by WHO [29-32]. The proportion of individuals with vaccine contraindications and pregnant women in Chinese population is listed in Table S3. We generated the proportion of individuals with at least 1 underlying condition of age group a, P_a, by using the following equation

$$P_a = 1 - [(1 - p(\mathrm{C}_1))(1 - p(\mathrm{C}_2)) \times \ldots \times (1 - p(\mathrm{C}_n)] \tag{28}$$

Where C_n $(n = 1, 2, 3, \ldots, 37)$ represents the underly conditions listed in Table S3 and $p(C_n)$ represents the proportion of individuals with underlying condition C_n. We then used the ratio between real and estimated probability of individuals with at least 1 underlying condition reported in the literatures (68.2%) [33-35] to adjust probability of each group.

Table S3. The proportion of pregnant women and vaccine contraindications by age groups.

Proportion (%)	Age group (years)																	
	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
Pregnant women	0.0	0.0	0.0	0.7	5.3	10.3	5.2	2.6	0.7	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Contraindications	0.2	0.1	0.1	0.1	0.2	0.2	0.3	0.5	0.7	0.9	1.2	1.7	2.2	2.7	3.2	3.2	2.8	2.2
Liver cancer due to NASH	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Colon and rectum cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.3	0.4	0.6	0.8	1.0	1.0	0.9	0.7
Lip and oral cavity cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Nasopharynx cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.1
Other pharynx cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gallbladder and biliary tract cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Pancreatic cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Malignant skin melanoma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Ovarian cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Testicular cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Kidney cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Bladder cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.2	0.1	0.1
Brain and central nervous system cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Thyroid cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Mesothelioma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Larynx cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0
Tracheal, bronchus, and lung cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.3	0.4	0.4	0.4	0.3
Breast cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.3	0.3	0.4	0.5	0.6	0.6	0.6	0.6	0.5	0.5

Cervical cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0
Uterine cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0
Prostate cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.4	0.5	0.6	0.6	0.3
Esophageal cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.2	0.2	0.1
Stomach cancer	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.3	0.3	0.4	0.4	0.4	0.2
Liver cancer due to hepatitis B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Liver cancer due to hepatitis C	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Liver cancer due to alcohol use	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Liver cancer due to other causes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Myelodysplastic, myeloproliferative, and	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.3	0.4	0.4	0.4	0.4	0.3
Acute lymphoid leukemia	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Chronic lymphoid leukemia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Acute myeloid leukemia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Chronic myeloid leukemia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other leukemia	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Hodgkin lymphoma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-Hodgkin lymphoma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1
Multiple myeloma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other malignant neoplasms	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.2	0.2	0.3	0.3	0.2	0.2

5 Vaccine administration capacity

We systematically collected information about COVID-19 vaccine administer in China from the press conferences of the Joint Prevention and Control Mechanism of the State Council [36]. The first data was recorded on November 30, 2020. At that time, the vaccination program was targeting all individuals aged between 18 and 59 years. On April 1, 2021, the target population was extended to include all individuals aged 18+ years. Table S4 shows the cumulative number of doses administered over time.

Since the number of administrated doses was not released every day, we interpolate the cumulative number of doses using an exponential model. The model is specified as,

$$N_t = N_0 e^{rt} \tag{29}$$

where, N_0 and N_t represent the cumulative number of doses at time 0 and *t*, respectively, and r is the growth rate.

The obtained fit until May 23, 2021 has a root mean square error (RMSE) of 8.298 (Figure S2 A). The increasing trend in the number of doses cannot continue to grow indefinitely. As such, we cupped the vaccination capacity at 17.53 million doses per day, as observed on June 2, 2021 (Fig. S2B). This capacity threshold (i.e., 17.53 million per day) corresponds to 294,234 doses per day for Shanghai (population of about 24 million) and is kept constant until the end of the simulation.



Figure S2. Modelled vaccine capacity. A Original and fitted cumulative number of doses administrated. **B** Projected daily vaccine capacity for the baseline scenario. Dots and lines represent empirical and fitted data.

Table S4. Cumulative number of COVID-19 doses administered in China.

Date	Cumulative doses	Date	Cumulative doses
2020-11-30	1,500,000	2021-04-17	189,809,000
2020-12-31	4,500,000	2021-04-18	192,127,000
2021-01-09	9,000,000	2021-04-19	195,022,000
2021-01-13	10,000,000	2021-04-20	198,965,000
2021-01-26	22,767,000	2021-04-21	204,191,000
2021-01-31	24,000,000	2021-04-22	211,223,000
2021-02-03	31,236,000	2021-04-23	216,084,000
2021-02-09	40,520,000	2021-04-24	220,309,000
2021-02-28	52,000,000	2021-04-25	224,901,000
2021-03-14	64,980,000	2021-04-26	229,489,000
2021-03-20	74,956,000	2021-04-27	235,976,000
2021-03-22	80,463,000	2021-04-28	243,905,000
2021-03-23	82,846,000	2021-04-29	253,463,000
2021-03-24	85,859,700	2021-04-30	265,064,000
2021-03-25	91,346,000	2021-05-01	270,406,000
2021-03-26	97,470,000	2021-05-02	275,338,000
2021-03-27	102,410,000	2021-05-03	279,905,000
2021-03-28	106,613,000	2021-05-04	284,595,000
2021-03-29	110,962,000	2021-05-05	289,627,000
2021-03-30	114,690,000	2021-05-06	297,734,000
2021-03-31	119,821,000	2021-05-07	308,226,000
2021-04-01	126,616,000	2021-05-08	317,586,000
2021-04-02	133,800,999	2021-05-09	324,307,000
2021-04-03	136,677,000	2021-05-10	332,964,000
2021-04-04	139,970,000	2021-05-11	342,697,000
2021-04-05	142,802,000	2021-05-12	354,272,000
2021-04-06	145,392,000	2021-05-13	366,910,000
2021-04-07	149,071,000	2021-05-14	380,633,000
2021-04-08	155,150,000	2021-05-15	392,987,000
2021-04-09	161,121,000	2021-05-16	406,938,000
2021-04-10	164,471,000	2021-05-17	421,991,000
2021-04-11	167,343,000	2021-05-18	435,689,000
2021-04-12	171,928,000	2021-05-19	449,511,000
2021-04-13	175,623,000	2021-05-20	466,698,000
2021-04-14	179,216,000	2021-05-21	483,343,000
2021-04-15	183,536,000	2021-05-22	497,272,000
2021-04-16	187,368,000	2021-05-23	510,858,000

6 Additional results for the baseline analysis

In addition to the results reported in Fig. 2, here we show other metrics of COVID-19 burden. In particular, the relative change in the number of symptomatic infections (Fig. S3B) and hospitalized patients (Fig. S3D) are similar to those estimated for the infections (Fig. 2B); the number of patients aged 0-2 years requiring admission to an ICU is 0 since the corresponding rate is 0 (Fig. S3F).



Figure S3. Baseline analysis – metric of COVID-19 burden. A Cumulative number of symptomatic infections (mean and 95% CI) after 1 year for the *reference scenario* without interventions and the three

analyzed vaccination strategies. *Reference scenario* indicates no vaccination and no NPIs with $R_0 = 2.5$ at the beginning of the simulation. Symptomatic infections comprise both unvaccinated and vaccinated individuals. The bar corresponds to the mean value, while the vertical line represents 95% quantile interval. **B** Reduction in the number of symptomatic infections (mean and 95% CI) with respect to the *reference scenario* in different age groups and the total population. The relative reduction is defined as the estimated number of infections after 1 year since the introduction of the initially infected individuals under the *reference scenario* minus the one under the vaccination strategy, relative to the estimated number under the *reference scenario*. **C** As A, but for cumulative number of hospitalized cases. **D** As B, but for reduction in hospitalized cases. **E** As A, but for cumulative number of ICU cases. **F** As B, but for reduction in ICU cases.

7 Sensitivity analyses

7.1 leaky vaccine

In the baseline scenario, we showed the results considering an "all-or-nothing" vaccine model (Fig. 2A-B). To explore the robustness of the results to the choice of the vaccine model, we used a 'leaky' vaccine as a sensitivity analysis. The finding is very consistent to that using "all-or-nothing" model (Fig. S4).



Figure S4. Sensitivity analysis on the vaccine model. A Estimated reproduction number R_e (mean and 95% CI) at the start of epidemic for three analyzed vaccination strategies. **B** Cumulative number of infections (mean and 95% CI) after 1 year for the *reference scenario* and the three analyzed vaccination strategies. **C** Reduction in the number of infections (mean and 95% CI) due to vaccination with respect to the *reference scenario*.

7.2 Initial number of infected individuals

In the baseline analysis, we used 40 infected individuals to initialize the epidemic (Fig. 2A-B). To explore the robustness of the results to this choice, we varied the initial number of infected individuals by assuming 10, 20, and 100 seeds. The estimated values of R_e are independent with number of seeds; the number of infections is not affected as well (Fig. S5).



Figure S5. Sensitivity analysis on the initial number of infected individuals. A Estimated reproduction number R_e (mean and 95% CI) at the start of epidemic for three analyzed vaccination strategies. **B** Cumulative number of infections (mean and 95% CI) after 1 year for the *reference scenario* and three analyzed vaccination strategies. **C** Reduction in infections (mean and 95% CI) due to vaccination with respect to the *reference scenario*.

7.3 Homogeneous susceptibility to infection by age

In the main analysis, we considered age-specific susceptibility to infection as estimated in ref.[10] (Fig. 2A-B). Here we explored a scenario where we assumed homogenous susceptibility to infection by age. All the obtained results are very consistent with those obtained in the main analysis (Fig. S6).



Figure S6. Sensitivity analysis assuming homogeneous susceptibility to infection by age. A Estimated reproduction number R_e (mean and 95% CI) at the start of epidemic for the three analyzed vaccination strategies. **B** Cumulative number of infections (mean and 95% CI) after 1 year for the *reference scenario* and the three analyzed vaccination strategies. **C** Reduction in infections (mean and 95% CI) due to vaccination with respect to the *reference scenario*.

7.4 Natural immunity

In the baseline analysis, we considered a population with no pre-existing natural immunity (Fig. 2A-B). We performed a sensitivity analysis where we considered that 10%, 20%, and 30% of the population had natural immunity before the start of the epidemic. The addition of natural immunity remarkably affects the results both in terms of transmissibility potential (Fig. S7A) and infections (Fig. S7B-C).



Figure S7. Sensitivity analysis on the natural immunity. A Estimated reproduction number R_e (mean and 95% CI) at the start of epidemic for the three analyzed vaccination strategies. **B** Cumulative number of infections (mean and 95% CI) after 1 year for the *reference scenario* and the three analyzed vaccination strategies. **C** Reduction in infections (mean and 95% CI) due to vaccination with respect to the *reference scenario*.

7.5 Vaccine efficacy

In the baseline analysis, we considered a two-dose vaccine whose efficacy against SARS-CoV-2 infections was set to 73.5% [11] for all age groups (Fig. 2A-B). Here we performed three sensitivity analyses on the VE. In the first one, we varied the overall vaccine efficacy (Fig. S8); second, we varied the vaccine efficacy for individuals aged 3-17 and 60+ years relative to that of individuals aged 18-59 years (Fig. S9); third, we use explored different times from the administration of the second dose and maximum protection (Fig. S10).



Figure S8. Sensitivity analysis on the vaccine efficacy. A Estimated reproduction number R_e (mean and 95% CI) at the start of epidemic for the three analyzed vaccination strategies. **B** Cumulative number of infections (mean and 95% CI) after 1 year for the *reference scenario* and the three analyzed vaccination strategies. **C** Reduction in infections (mean and 95% CI) due to vaccination with respect to the *reference scenario*.



Figure S9. Sensitivity analysis on the vaccine efficacy for individuals aged 3-17 and 60+ years relative to that of individuals aged 18-59 years. A Estimated reproduction number R_e (mean and 95% CI) at the

start of epidemic for the three analyzed vaccination strategies. **B** Cumulative number of infections (mean and 95% CI) after 1 year for the *reference scenario* and the three analyzed vaccination strategies. **C** Reduction in the number of infections (mean and 95% CI) due to vaccination with respect to the *reference scenario*.



Figure S10. Sensitivity analysis of the time between vaccination and maximum protection. A Estimated reproduction number R_e (mean and 95% CI) at the start of epidemic for the three analyzed vaccination strategies. **B** Cumulative number of infections (mean and 95% CI) after 1 year for the *reference scenario* and the three analyzed vaccination strategies. **C** Reduction in the number of infections (mean and 95% CI) due to vaccination with respect to the *reference scenario*.

7.6 Time interval between the two doses

In the baseline analysis, we considered a two-dose vaccine with a 21-day interval between the two doses (Fig. 2A-B). Here we proposed a sensitivity analysis on this time interval, assuming a 14-day interval. All the obtained results are very consistent with those obtained in the baseline analysis (Fig. S11).



Figure S11. Sensitivity analysis on time intervals between the two doses. A Estimated reproduction number R_e (mean and 95% CI) at the start of epidemic for the three analyzed vaccination strategies. **B** Cumulative number of infections (mean and 95% CI) after 1 year for the *reference scenario* and the three analyzed vaccination strategies. **C** Reduction in the number of infections (mean and 95% CI) due to vaccination with respect to the *reference scenario*.

8 Scenario 1: Delaying the start of the epidemic

We tested to what extent the start of a new epidemic wave needs to be delayed (e.g., by keeping strict restriction for international travels) to allow the immunity to build up in the population, potentially reaching herd immunity levels in Fig. 3A-C. Here we reported the impact of delaying the start of the epidemic on vaccine coverage (Fig. S12A-C) and daily incidence of new infections (Fig. S12D-F). In particular, the reduction in deaths is similar to those estimated for the infections (Fig. 3C).



Figure S12. Impact of delaying the start of the epidemic on vaccine coverage and daily incidence of new infections. A Cumulative vaccination coverage of strategy 1. **B** As A, but for strategy 2. **C** As A, but for strategy 3. **D** Daily incidence of new infection for strategy 1. **E** As A, but for strategy 2. **F** As A, but for strategy 3.



Figure S13. Impact of delaying the start of the epidemic on deaths. A Cumulative number of deaths (mean and 95% CI) after 1 year for the *reference scenario* and three analyzed vaccination strategies. **B** Reduction in deaths (mean and 95% CI) due to vaccination with respect to the *reference scenario*.

9 Scenario 2: Adopting NPIs in case of a new outbreak

We investigated the synergetic effect of vaccination programs combined with non-pharmaceutical interventions (NPIs) of different intensity in Fig. 3D-F. Here we reported the impact of adopting NPIs on daily incidence of new infections (Fig. S14). In particular, the reduction in deaths is similar to those estimated for the infections (Fig. 3F).



Figure S14. Impact of adopting NPIs in case of a new outbreak on daily incidence of new infections. A Vaccine coverage of strategy 1. **B** Vaccine coverage of strategy 2. **C** Vaccine coverage of strategy 3.



Figure S15. Impact of adopting different intensity of NPIs on deaths. A Cumulative number of deaths (mean and 95% CI) after 1 year for the *reference scenario* and three analyzed vaccination strategies. **B** Reduction in deaths (mean and 95% CI) due to vaccination with respect to the *reference scenario*.

10 Scenario 3: Delaying the start of the epidemic and adopting NPIs

To further improve the potential for vaccination-induced herd immunity against the SARS-CoV-2, we tested the combination of two scenarios mentioned above: delaying the start of the epidemic and adopting NPIs in case of a new outbreak in Fig.4. Here we reported the impact of the above two scenarios on infections and on deaths. In particular, the reduction in infections and deaths is more than 92% (Fig. S16 and S17).



Figure S16. Impact of delaying the start of the epidemic, and adopting NPIs on infections. A Reduction in infections due to vaccination with respect to the *reference scenario* for strategy 1. **B** As A, but for strategy 2. **C** As A, but for strategy 3.



Figure S17. Impact of delaying the start of epidemic, and adopting NPIs on deaths. A Reduction in deaths due to vaccination with respect to the *reference scenario* for strategy 1. **B** As A, but for strategy 2. **C** As A, but for strategy 3.

11 Additional results about the herd immunity threshold

We showed the relation between R_e and vaccine coverage in Fig. 5. Here we performed two sensitivity analyses: exploring impact of the contact matrix considering an independently estimated contact matrix for the Chinese population (Fig. S18), and vaccine efficacy. The obtained results show that R_e is very consistent with those obtained in the main analysis, and the infections can remarkably decrease with higher VE (Fig. S19 and S20).



Figure S18. Comparison of contact matrix in Shanghai and China. A Shanghai contact matrix. **B** Chinese contact matrix [37].



Figure S19. Impact of contact matrix on estimated reproduction number R_e, vaccination coverage for strategy 2, and infection attack rate. A Estimated reproduction number R_e as a function of the vaccination coverage using the contact matrix for China estimated in ref. [37]. Colors refer to the three analyzed vaccination strategies. The shaded area in gray indicates the herd immunity threshold R_e =1. The numbers around the line indicate where the threshold is crossed. **B** Age-specific vaccination coverage over time for strategy 2 in

the absence of transmission. The crossed point of two dotted lines corresponds to the time the coverage reached the herd immunity threshold. **C** Infection attack rate after 1 simulated year as a function of vaccine coverage. The transmission is simulated with the initial vaccination coverage and no vaccination after the infection is seeded.



Figure S20. Impact of vaccine efficacy on the reproduction number R_e and the infection attack rate. **A** Estimated effective reproduction number R_e (mean and 95% CI) as a function of the vaccination coverage, assuming an 85% efficacious vaccine and no transmission. Colors refer to the three vaccination strategies. The shaded area in gray indicates the herd immunity threshold R_e=1. The numbers around the line indicate where R_e crosse this threshold. **B** As A, but with a 95% efficacious vaccine. **C** The infection attack rate after 1 simulated year as a function of vaccine coverage with an 85% efficacious vaccine. The transmission is simulated with the initial vaccine coverage and there is no longer vaccination after the infection is seeded. **D** As C, but with a 95% efficacious vaccine

12 US-like scenario

In the baseline analysis, we considered the scenario in China with VE=73.5% [11] and no initial natural immunity [9] (Fig. 2A-B). Here we proposed a sensitivity analysis where we simulated a US-like scenario, where VE=95% [38] and the initial fraction of naturally immune population is set at 22% [39], finding remarkably different results both in terms of transmission potential and number of infections (Fig. S21).



Figure S21. Comparison between a US-like scenario (VE=95% [38], initial fraction of naturally immune population=22% [39]) and China (VE=73.5% [11], no initial natural immunity [9]). A Estimated reproduction number R_e (mean and 95% CI) at the start of epidemic for the three analyzed vaccination strategies. **B** Cumulative number of infections (mean and 95% CI) after 1 year for the *reference scenario* and the three analyzed vaccination strategies. **C** Reduction in the number of infections (mean and 95% CI) due to vaccination with respect to the *reference scenario*.

13 SI References

1 Zhang, J. *et al.* Patterns of human social contact and contact with animals in Shanghai, China. *Sci Rep* **9**, 15141, doi:10.1038/s41598-019-51609-8 (2019).

2 Liu, Q. H. *et al.* Measurability of the epidemic reproduction number in data-driven contact networks. *Proc Natl Acad Sci U S A* **115**, 12680-12685, doi:10.1073/pnas.1811115115 (2018).

3 Sun, K. *et al.* Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. *Science* **371**, doi:10.1126/science.abe2424 (2021).

4 Pan, A. *et al.* Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. *JAMA* **323**, 1915-1923, doi:10.1001/jama.2020.6130 (2020).

5 Li, Q. *et al.* Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med* **382**, 1199-1207, doi:10.1056/NEJMoa2001316 (2020).

6 Chinazzi, M. *et al.* The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. *Science* **368**, 395-400, doi:10.1126/science.aba9757 (2020).

7 Wu, J. T., Leung, K. & Leung, G. M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* **395**, 689-697, doi:10.1016/S0140-6736(20)30260-9 (2020).

8 Pang, X. *et al.* Cold-chain food contamination as the possible origin of Covid-19 resurgence in Beijing. *Natl Sci Rev* (2020).

9 Chen, X. *et al.* Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. *Lancet Glob Health* **9**, e598-e609, doi:10.1016/S2214-109X(21)00026-7 (2021).

10 Hu, S. *et al.* Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. *Nat Commun* **12**, 1533, doi:10.1038/s41467-021-21710-6 (2021).

11 Al Kaabi, N. *et al.* Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *JAMA*, doi:10.1001/jama.2021.8565 (2021).

12 Palacios, R. *et al.* (SSRN, 2021).

13 Poletti, P. *et al.* Association of Age With Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to Patients With Confirmed SARS-CoV-2 Infection in Italy. *JAMA Netw Open* **4**, e211085, doi:10.1001/jamanetworkopen.2021.1085 (2021).

14 Yang, J. *et al.* Disease burden and clinical severity of the first pandemic wave of COVID-19 in Wuhan, China. *Nat Commun* **11**, 5411, doi:10.1038/s41467-020-19238-2 (2020).

15 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* **382**, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).

16 Washington, N. L. *et al.* Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. *Cell* **184**, 2587-2594 e2587, doi:10.1016/j.cell.2021.03.052 (2021).
17 Gaymard, A. *et al.* Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021. *Euro Surveill* **26**, doi:10.2807/1560-7917.ES.2021.26.9.2100133 (2021).
18 Leung, K., Shum, M. H., Leung, G. M., Lam, T. T. & Wu, J. T. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. *Euro Surveill* **26**, doi:10.2807/1560-7917.ES.2020.26.1.2002106 (2021).
19 Zhao, S. *et al.* Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the UK: an early data-driven analysis. *J Travel Med* **28**, doi:10.1093/jtm/taab011 (2021).
20 Graham, M. S. *et al.* Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. *Lancet Public Health* **6**, e335-e345, doi:10.1016/S2468-2667(21)00055-4 (2021).
21 Volz, E. *et al.* Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature* **593**, 266-269, doi:10.1038/s41586-021-03470-x (2021).
22 Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* **372**, doi:10.1126/science.abg3055 (2021).
23 Carl A.B. Pearson, T. W. R., Nicholas Davies, Adam J Kucharski, CMMID COVID-19 working group, W John Edmunds & Rosalind M Eggo. Estimates of severity and transmissibility of novel SARS-CoV-2 variant 501Y.V2 in South Africa. (2021).
24 Faria, N. R. *et al.* Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science* **372**, 815-821, doi:10.1126/science.abh2644 (2021).
25 Emergencies, S. A. G. f. SPI-M-O: Consensus Statement on COVID-19, 12 May 2021. (2021).
26 Challen, R. *et al.* Early epidemiological signatures of novel SARS-CoV-2 variants: establishment of B.1.617.2 in England. *medRxiv*, 2021.2006.2005.21258365, doi:10.1101/2021.06.05.21258365 (2021).
27 Dagpunar, J. Interim estimates of increased transmissibility, growth rate, and reproduction number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom. *medRxiv*, 2021.2006.2003.21258293, doi:10.1101/2021.06.03.21258293 (2021).
28 Diekmann, O., Heesterbeek, J. A. & Metz, J. A. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. *J Math Biol* **28**, 365-382, doi:10.1007/BF00178324 (1990).
29 World Health Organization. *WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination*, <https://www.who.int/publications/i/item/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination> (2020).

30 World Health Organization. *Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing*, <https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1> (2021).

31 World Health Organization. *Pfizer BioNTech COVID-19 vaccine: What you need to know*, <https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine#:~:text=WHO's%20Strategic%20Advisory%20Group%20of,vaccine%20is%20safe%20and%20effective> (2021).

32 World Health Organization. *Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience)*, <https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1> (2021).

33 National Bureau of Statistics. *China Population & Employment Statistics Yearbook 2019*, <https://navi.cnki.net/KNavi/YearbookDetail?pcode=CYFD&pykm=YZGRL&bh=> (2019).

34 United Nations. *UN 2020 estimation*, <https://population.un.org/wpp/Download/Standard/Population/> (

35 Wang, H. H. *et al.* Epidemiology of multimorbidity in China and implications for the healthcare system: cross-sectional survey among 162,464 community household residents in southern China. *BMC Med* **12**, 188, doi:10.1186/s12916-014-0188-0 (2014).

36 National Health Commision of the People's Republic of China. *Update on the doses of COVID-19 vaccine administration*, <http://www.nhc.gov.cn/xcs/yqjzqk/list_gzbd.shtml> (

37 Mistry, D. *et al.* Inferring high-resolution human mixing patterns for disease modeling. *Nat Commun* **12**, 323, doi:10.1038/s41467-020-20544-y (2021).

38 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New Engl J Med* **383**, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).

39 Centers for Disease Control and Prevention. Nationwide Commercial Laboratory Seroprevalence Survey. (2021).